

30 April 2024

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Final results for the year ended 31 December 2023

Cizzle Biotechnology, the UK based diagnostics developer, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2023.

The Annual Financial Report is available via [RNS to insert link] and will shortly be available to view on the Company's website at: <https://cizzlebiotechnology.com>

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited - Joint Broker and Financial Adviser
John Depasquale
George Payne

+44(0) 20 3328 5656

Novum Securities Limited – Joint Broker
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited – Financial Public Relations
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin-out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn